Zumutor Biologics Raises $7.3 Million to Advance Cancer Immunotherapy Trials in India and US

Bengaluru-headquartered biotech firm Zumutor Biologics has successfully closed a Series B funding round, raising $7.3 million (approximately ₹70 crore). The capital infusion, primarily from existing investors Accel and Bharat Innovation Fund, along with new participation from Premji Invest, Ashish Kacholia, and Raj Dandu, is earmarked for advancing the company’s cancer immunotherapy drug, ZM008.

The funding will support the completion of the ongoing US FDA Phase 1 clinical study for ZM008, both as a monotherapy and in combination regimens. Crucially, the investment will also facilitate the initiation of Phase 1B expansion cohorts and global Phase 2 studies, with a significant focus on expanding trials within India.

Key facts

Aspect	Details
Funding Round	Series B
Amount Raised	$7.3 Million (approx. ₹70 Crore)
Key Investors	Accel, Bharat Innovation Fund (existing); Premji Invest, Ashish Kacholia, Raj Dandu (new)
Primary Goal	Advance ZM008 clinical trials (US Phase 1 completion, global Phase 2 initiation including India)

Advancing Immunotherapy for Cancer Treatment

Founded in 2013 by Kavitha Iyer Rodrigues, Zumutor Biologics specializes in developing immunotherapy drugs designed to activate the body’s natural immune cells, particularly natural killer (NK) cells. These drugs aim to enhance the immune system’s ability to identify and eliminate tumor cells, thereby improving cancer treatment outcomes.

The company’s lead drug candidate, ZM008, is described as a first-in-class NK cell checkpoint inhibitor. This innovative approach seeks to unleash the inherent power of innate immunity to combat cancer. Human trials for ZM008 commenced in 2024, marking a significant step in bringing this novel therapy to patients.

Clinical Progress and Future Expansion

Maloy Ghosh, Zumutor’s chief scientific officer, highlighted the promising early clinical data from the ongoing Phase 1 study of ZM008, which indicates the differentiated potential of NK checkpoint therapy for solid tumors. Building on these findings, the company plans to expand into dose expansion cohorts and combination studies across various tumor types. The expansion of trials into India for Phase 2 studies underscores the company’s commitment to global development and accessibility.

Zumutor Biologics leverages two proprietary ‘Antibody Engineering Platforms’ to create its immunotherapies. These platforms are designed to target innate immunity and regulate the tumor microenvironment, offering a sophisticated approach to cancer treatment. The company previously raised $6.2 million in its Series A4 funding round in 2021, led by Siana Capital. While headquartered in the US, Zumutor maintains a vital R&D laboratory in Bengaluru, India.

Government Support and Biotech Growth in India

This funding round aligns with a broader national push to bolster India’s biotech sector. The Indian government has demonstrated its commitment through initiatives such as the ‘Biopharma SHAKTI’ scheme, announced by Finance Minister Nirmala Sitharaman, with an outlay of ₹10,000 crore. This scheme, alongside a single-window clearance portal for biological research and funding support via the BIRAC SEED scheme, aims to foster innovation and growth among biotech startups.

Investors are increasingly recognizing the potential within India’s bioeconomy, which is projected to reach a $300 billion market opportunity by 2030. Recent funding activities in the sector include StrainX Bioworks raising $13 million for its bio-manufacturing facility and Cellogen Therapeutics securing ₹20 crore to advance its CAR-T clinical programs. These developments collectively highlight a vibrant and expanding biotech ecosystem in India, poised for significant contributions to global healthcare.

Source: Inc42, https://inc42.com/buzz/zumutor-biologics-secures-7-3-mn-to-advance-clinical-trials-for-cancer-therapy/